Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Ad5/3-D24-GMCSF; AdV5/3-D24-GM-CSF; CGTG-102; ONCOS-102

Latest Information Update: 07 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Oncos Therapeutics
  • Developer AstraZeneca; Ludwig Institute for Cancer Research; Oncos Therapeutics; SOTIO; Targovax
  • Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
  • Mechanism of Action Cell death stimulants; Granulocyte-macrophage colony-stimulating factor expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma; Ovarian cancer; Mesothelioma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Malignant-mesothelioma
  • Phase I/II Colorectal cancer; Ovarian cancer
  • Phase I Malignant melanoma
  • Discontinued Prostate cancer; Soft tissue sarcoma; Solid tumours

Most Recent Events

  • 22 Jun 2023 Agenus and Targovax withdraws a phase II trial prior to enrolment in Malignant melanoma (Combination therapy, Inoperable/Unresectable, Metastatic, Treatment-resistant, Monotherapy, Second-line therapy or greater) (Intratumoral, Injection) due to strategic reason (NCT05561491)
  • 02 Jun 2023 Immunogenicity and efficacy data from the phase I/II MESOS trial in Mesothelioma presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
  • 25 Jun 2022 Targovax and MedImmune complete a phase I/II trial for Colorectal cancer and Ovarian Cancer (Combination therapy, Second-line therapy or greater) in USA (NCT02963831)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top